Fig. 2: Overexpression of C/EBPα-p42 reduces the sensitivity of FLT3 ITD AML cells to FLT3i in vitro.

A C/EBPα-p42 was overexpressed in MV-4-11 and MOLM-13 cell lines, as confirmed by western blotting. n = 3 independent experiments. B GSEA plots of the C/EBPα-regulated genes in C/EBPα-p42-overexpressing MV-4-11 and MOLM-13 cells. C Functional enrichment analysis of the differential signalling pathways in C/EBPα-p42-overexpressing MV-4-11 and MOLM-13 cells. D Changes in STAT5, AKT and ERK phosphorylation in MV-4-11 and MOLM-13 cells with or without C/EBPα-p42 overexpression under quizatinib (0.3, 1, or 3 nM) or gilteritinib (1, 3 or 10 nM) in MV-4-11 and quizatinib (1, 3, or 10 nM) or gilteritinib (3, 10, or 30 nM) in MOLM-13 for 2 h. E Quantification of the phosphorylation changes in (D). n = 3 independent experiments. Data are Means ± SEM. Significance was analyzed by equal variance two-tailed t test.*P < 0.05, **P < 0.01, ***P < 0.001. F Growth curve changes in MV-4-11 and MOLM-13 cells with or without C/EBPα-p42 overexpression treated with DMSO, quizartinib or gilteritinib. n = 3 independent experiments. Data are Means ± SEM. Significance was analyzed by equal variance two-tailed t test.*P < 0.05, **P < 0.01, ***P < 0.001. Exact p values in Source Data file. Data for all graphs in Source Data file.